The molecular subtyping proposed by Moss et al. suggests a role for FGFR3 inhibitors in both LG- and HG-UTUC [12,86]; moreover, immune checkpoint inhibitors might be effective in the cohort of patients belonging to Cluster 4 (Figure 2). Here, FGFR3 is linked to renal pelvis/ureter urothelial carcinoma.